Download PDF
Onkologische Welt 2012; 03(04): 177-178
DOI: 10.1055/s-0038-1630206
ASCO – Gynäkologische Onkologie
Schattauer GmbH

Ovarialkarzinom: Diskussion um Therapiestandard in der Primärtherapie

Birgit Pohlmann
Further Information

Publication History

Publication Date:
01 February 2018 (online)

    Permissions and Reprints

In der Primärtherapie des Ovarialkarzinoms wird die Frage diskutiert, ob die wöchentliche Gabe von Paclitaxel (80 mg/m², Tag 1,8,15) plus Carboplatin (AUC 6, Tag 1, q3W) (dd-TC) das etablierte 3-wöchentliche Regime mit Paclitaxel (180 mg/m², Tag 1) plus Carboplatin (AUC 6, Tag 1) (c-TC) als Standard in der Primärtherapie des epithelialen Ovarialkarzinoms ablösen. Eine endgültige Klärung steht jedoch noch aus, erläuterte Prof. Andreas du Bois, Essen.

 

  • Literatur

  • 1 Katsumata N. et al. Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. J Clin Oncol 2012; 30 (suppl.): Abstract 5003.
    Google Scholar
  • 2 Vergote I. et al. Randomized phase III study of Erlotinib vs. observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: GCIG and EORTC-GCG study. J Clin Oncol 2012; 30 (suppl.): Abstract LBA5000.
    CrossrefGoogle Scholar
  • 3 de Gregorio N. et al. Outcome of patients with borderline ovarian tumors: results of the multicenter AGO ROBOT study. J Clin Oncol 2012; 30 (suppl.): Abstract LBA5005.
    Google Scholar
  • 4 Pujade-Lauraine E. et al. AURELIA: A randomized phase III trial evaluating Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer. J Clin Oncol 2012; 30 (suppl.): Abstract LBA5002.
    CrossrefGoogle Scholar
  • 5 Parker C. et al. Final overall survival analysis results from the phase III, double-blind, randomized multinational study of radium-223 chloride in the treatment of patients with castration-resistent prostate cancer with bone metastases. J Clin Oncol 2012; 30 (suppl.): Abstract LBA4512.
    CrossrefGoogle Scholar
  • 6 Oza A. et al. Olaparib plus paclitaxel plus carboplatin followed by olaparib maintenance treatment in patients with platinum-sensitive recurrent serous ovarian cancer: randomized open-label phase II study. J Clin Oncol 2012; 30 (suppl): Abstract 5001.
    Google Scholar